147 related articles for article (PubMed ID: 18216394)
21. Structural basis for a non-phosphorus-containing cyclic peptide binding to Grb2-SH2 domain with high affinity.
Li P; Zhang M; Peach ML; Zhang X; Liu H; Nicklaus M; Yang D; Roller PP
Biochem Biophys Res Commun; 2003 Aug; 307(4):1038-44. PubMed ID: 12878216
[TBL] [Abstract][Full Text] [Related]
22. N-terminal carboxyl and tetrazole-containing amides as adjuvants to Grb2 SH2 domain ligand binding.
Burke TR; Yao ZJ; Gao Y; Wu JX; Zhu X; Luo JH; Guo R; Yang D
Bioorg Med Chem; 2001 Jun; 9(6):1439-45. PubMed ID: 11408162
[TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of conformationally constrained Grb2 SH2 domain binding peptides employing alpha-methylphenylalanyl based phosphotyrosyl mimetics.
Oishi S; Karki RG; Kang SU; Wang X; Worthy KM; Bindu LK; Nicklaus MC; Fisher RJ; Burke TR
J Med Chem; 2005 Feb; 48(3):764-72. PubMed ID: 15689160
[TBL] [Abstract][Full Text] [Related]
24. Adaptor signalling proteins Grb2 and Grb7 are recruited by human G6f, a novel member of the immunoglobulin superfamily encoded in the MHC.
De Vet EC; Aguado B; Campbell RD
Biochem J; 2003 Oct; 375(Pt 1):207-13. PubMed ID: 12852788
[TBL] [Abstract][Full Text] [Related]
25. Utilization of a nitrobenzoxadiazole (NBD) fluorophore in the design of a Grb2 SH2 domain-binding peptide mimetic.
Shi ZD; Karki RG; Oishi S; Worthy KM; Bindu LK; Dharmawardana PG; Nicklaus MC; Bottaro DP; Fisher RJ; Burke TR
Bioorg Med Chem Lett; 2005 Mar; 15(5):1385-8. PubMed ID: 15713392
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and utilization of chiral alpha-methylated alpha-amino acids with a carboxyalkyl side chain in the design of novel Grb2-SH2 peptide inhibitors free of phosphotyrosine.
Long YQ; Xue T; Song YL; Liu ZL; Huang SX; Yu Q
J Med Chem; 2008 Oct; 51(20):6371-80. PubMed ID: 18821748
[TBL] [Abstract][Full Text] [Related]
27. The C-terminal SH3 domain of the adapter protein Grb2 binds with high affinity to sequences in Gab1 and SLP-76 which lack the SH3-typical P-x-x-P core motif.
Lewitzky M; Kardinal C; Gehring NH; Schmidt EK; Konkol B; Eulitz M; Birchmeier W; Schaeper U; Feller SM
Oncogene; 2001 Mar; 20(9):1052-62. PubMed ID: 11314042
[TBL] [Abstract][Full Text] [Related]
28. A fluorescence polarization based Src-SH2 binding assay.
Lynch BA; Loiacono KA; Tiong CL; Adams SE; MacNeil IA
Anal Biochem; 1997 Apr; 247(1):77-82. PubMed ID: 9126374
[TBL] [Abstract][Full Text] [Related]
29. Simultaneous assay of Src SH3 and SH2 domain binding using different wavelength fluorescence polarization probes.
Lynch BA; Minor C; Loiacono KA; van Schravendijk MR; Ram MK; Sundaramoorthi R; Adams SE; Phillips T; Holt D; Rickles RJ; MacNeil IA
Anal Biochem; 1999 Nov; 275(1):62-73. PubMed ID: 10542110
[TBL] [Abstract][Full Text] [Related]
30. Evidence for an interaction between the insulin receptor and Grb7. A role for two of its binding domains, PIR and SH2.
Kasus-Jacobi A; Béréziat V; Perdereau D; Girard J; Burnol AF
Oncogene; 2000 Apr; 19(16):2052-9. PubMed ID: 10803466
[TBL] [Abstract][Full Text] [Related]
31. Surface plasmon resonance thermodynamic and kinetic analysis as a strategic tool in drug design. Distinct ways for phosphopeptides to plug into Src- and Grb2 SH2 domains.
de Mol NJ; Dekker FJ; Broutin I; Fischer MJ; Liskamp RM
J Med Chem; 2005 Feb; 48(3):753-63. PubMed ID: 15689159
[TBL] [Abstract][Full Text] [Related]
32. Structural requirements for Tyr in the consensus sequence Y-E-N of a novel nonphosphorylated inhibitor to the Grb2-SH2 domain.
Long YQ; Yao ZJ; Voigt JH; Lung FD; Luo JH; Burke TR; King CR; Yang D; Roller PP
Biochem Biophys Res Commun; 1999 Nov; 264(3):902-8. PubMed ID: 10544028
[TBL] [Abstract][Full Text] [Related]
33. Functional implications of the conformational switch in AICD peptide upon binding to Grb2-SH2 domain.
Das S; Raychaudhuri M; Sen U; Mukhopadhyay D
J Mol Biol; 2011 Nov; 414(2):217-30. PubMed ID: 22001015
[TBL] [Abstract][Full Text] [Related]
34. Solution structure of the SH2 domain of Grb2 complexed with the Shc-derived phosphotyrosine-containing peptide.
Ogura K; Tsuchiya S; Terasawa H; Yuzawa S; Hatanaka H; Mandiyan V; Schlessinger J; Inagaki F
J Mol Biol; 1999 Jun; 289(3):439-45. PubMed ID: 10356320
[TBL] [Abstract][Full Text] [Related]
35. Alternative mode of binding to phosphotyrosyl peptides by Src homology-2 domains.
Qin C; Wavreille AS; Pei D
Biochemistry; 2005 Sep; 44(36):12196-202. PubMed ID: 16142918
[TBL] [Abstract][Full Text] [Related]
36. The intertwining of structure and function: proposed helix-swapping of the SH2 domain of Grb7, a regulatory protein implicated in cancer progression and inflammation.
Pias S; Peterson TA; Johnson DL; Lyons BA
Crit Rev Immunol; 2010; 30(3):299-304. PubMed ID: 20370637
[TBL] [Abstract][Full Text] [Related]
37. Discovery of 3-aminobenzyloxycarbonyl as an N-terminal group conferring high affinity to the minimal phosphopeptide sequence recognized by the Grb2-SH2 domain.
Furet P; Gay B; García-Echeverría C; Rahuel J; Fretz H; Schoepfer J; Caravatti G
J Med Chem; 1997 Oct; 40(22):3551-6. PubMed ID: 9357522
[TBL] [Abstract][Full Text] [Related]
38. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis.
Tanaka S; Pero SC; Taguchi K; Shimada M; Mori M; Krag DN; Arii S
J Natl Cancer Inst; 2006 Apr; 98(7):491-8. PubMed ID: 16595785
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic.
Gao Y; Luo J; Yao ZJ; Guo R; Zou H; Kelley J; Voigt JH; Yang D; Burke TR
J Med Chem; 2000 Mar; 43(5):911-20. PubMed ID: 10715157
[TBL] [Abstract][Full Text] [Related]
40. Examination of phosphoryl-mimicking functionalities within a macrocyclic Grb2 SH2 domain-binding platform.
Kang SU; Shi ZD; Worthy KM; Bindu LK; Dharmawardana PG; Choyke SJ; Bottaro DP; Fisher RJ; Burke TR
J Med Chem; 2005 Jun; 48(12):3945-8. PubMed ID: 15943469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
